A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

NCT02431208 PHASE1 COMPLETED

This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have relapsed or who have undergone autologous stem cell transplantation (ASCT). Cycle length will be 21 days in Cohorts A to C and 28 days in Cohorts D to F.

Details

Lead sponsor	Hoffmann-La Roche
Phase	PHASE1
Status	COMPLETED
Enrolment	85
Start date	Wed Jul 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Mar 19 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Multiple Myeloma

Interventions

• Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
• Daratumumab
• Lenalidomide
• Pomalidomide
• Dexamethasone

Countries

United States